Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma

Resistance to radiotherapy (IR), with consequent disease recurrence, continues to limit the efficacy of contemporary anticancer treatment for patients with hepatocellular carcinoma (HCC), especially in late stage. Despite accruing evidence implicating the PI3K/AKT signaling pathway in cancer-promoting hypoxia, cancerous cell proliferation and radiotherapy-resistance, it remains unclear which molecular constituent of the pathway facilitates adaptation of aggressive HCC cells to tumoral stress signals and drives their evasion of repeated IR-toxicity. This present study investigated the role of PDK1 signaling in IR-resistance, enhanced DNA damage repair and post-IR relapse, characteristic of aggressive HCC cells, while exploring potential PDK1-targetability to improve radiosensitivity. The study employed bioinformatics analyses of gene expression profile and functional protein–protein interaction, generation of IR-resistant clones, flow cytometry-based ALDH activity and side-population (SP) characterization, siRNA-mediated loss-of-PDK1function, western-blotting, immunohistochemistry and functional assays including cell viability, migration, invasion, clonogenicity and tumorsphere formation assays. We showed that the aberrantly expressed PDK1 characterizes poorly differentiated HCC CVCL_7955, Mahlavu, SK-HEP1 and Hep3B cells, compared to the well-differentiated Huh7 or normal adult liver epithelial THLE-2 cells, and independently activates the PI3K/AKT/mTOR signaling. Molecular ablation of PDK1 function enhanced susceptibility of HCC cells to IR and was associated with deactivated PI3K/AKT/mTOR signaling. Additionally, PDK1-driven IR-resistance positively correlated with activated PI3K signaling, enhanced HCC cell motility and invasiveness, augmented EMT, upregulated stemness markers ALDH1A1, PROM1, SOX2, KLF4 and POU5F1, increased tumorsphere-formation efficiency and suppressed biomarkers of DNA damage—RAD50, MSH3, MLH3 and ERCC2. Furthermore, the acquired IR-resistant phenotype of Huh7 cells was strongly associated with significantly increased ALDH activity, SP-enrichment, and direct ALDH1-PDK1 interaction. Moreover, BX795-mediated pharmacological inhibition of PDK1 synergistically enhances the radiosensitivity of erstwhile resistant cells, increased Bax/Bcl-2 apoptotic ratio, while suppressing oncogenicity and clonogenicity. We provide preclinical evidence implicating PDK1 as an active driver of IR-resistance by activation of the PI3K/AKT/mTOR signaling, up-modulation of cancer stemness signaling and suppression of DNA damage, thus, projecting PDK1-targeting as a putative enhancer of radiosensitivity and a potential new therapeutic approach for patients with IR-resistant HCC.

[1]  Haitao Zhao,et al.  Alterations in DNA Damage Repair Genes in Primary Liver Cancer , 2019, Clinical Cancer Research.

[2]  G. Moreno-Bueno,et al.  Contribution of Epithelial Plasticity to Therapy Resistance , 2019, Journal of clinical medicine.

[3]  U. Neumann,et al.  Treatment Strategies for Hepatocellular Carcinoma—A Multidisciplinary Approach , 2019, International journal of molecular sciences.

[4]  Shanshan Wang,et al.  Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies , 2018, Therapeutic advances in medical oncology.

[5]  M. Korc,et al.  Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells , 2018, Cell Death & Disease.

[6]  S. Zhang,et al.  LZTS2 inhibits PI3K/AKT activation and radioresistance in nasopharyngeal carcinoma by interacting with p85. , 2018, Cancer letters.

[7]  V. Jendrossek,et al.  New Insights into Protein Kinase B/Akt Signaling: Role of Localized Akt Activation and Compartment-Specific Target Proteins for the Cellular Radiation Response , 2018, Cancers.

[8]  Alan D. Lopez,et al.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level , 2017, JAMA oncology.

[9]  M. Falasca,et al.  Targeting PDK1 for Chemosensitization of Cancer Cells , 2017, Cancers.

[10]  D. Melisi,et al.  EMT and Treatment Resistance in Pancreatic Cancer , 2017, Cancers.

[11]  Greg M. Findlay,et al.  Protein Kinases in Pluripotency-Beyond the Usual Suspects. , 2017, Journal of molecular biology.

[12]  Alberto Puliafito,et al.  PDK1: At the crossroad of cancer signaling pathways. , 2017, Seminars in cancer biology.

[13]  R. Weinberg,et al.  EMT, CSCs, and drug resistance: the mechanistic link and clinical implications , 2017, Nature Reviews Clinical Oncology.

[14]  A. Puliafito,et al.  Serine/Threonine Kinase 3-Phosphoinositide-Dependent Protein Kinase-1 (PDK1) as a Key Regulator of Cell Migration and Cancer Dissemination , 2017, Cancers.

[15]  K. Freier,et al.  Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma , 2015, Expert opinion on therapeutic targets.

[16]  M. Wirth,et al.  Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells. , 2015, Cancer research.

[17]  A. Zygogianni,et al.  Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review. , 2015, World journal of hepatology.

[18]  M. Kastan,et al.  The DNA damage response: implications for tumor responses to radiation and chemotherapy. , 2015, Annual review of medicine.

[19]  C. Frenette,et al.  Current management of hepatocellular carcinoma. , 2014, Gastroenterology & hepatology.

[20]  M. Lomax,et al.  Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[21]  Yong Li,et al.  Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance , 2013, Cell Death and Disease.

[22]  L. Dawson,et al.  Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. , 2013, International journal of radiation oncology, biology, physics.

[23]  Qiang Yu,et al.  PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. , 2013, Cancer discovery.

[24]  Z. Gong,et al.  Inducible and repressable oncogene-addicted hepatocellular carcinoma in Tet-on xmrk transgenic zebrafish. , 2012, Journal of hepatology.

[25]  M. Falasca,et al.  Targeting PDK1 in cancer. , 2011, Current medicinal chemistry.

[26]  J. Llovet,et al.  Targeted therapies for hepatocellular carcinoma. , 2011, Gastroenterology.

[27]  D. Jain,et al.  Molecular Pathology of Hepatic Neoplasms: Classification and Clinical Significance , 2011, Pathology research international.

[28]  S. Knapp,et al.  The (un)targeted cancer kinome. , 2010, Nature chemical biology.

[29]  O. Hammarsten,et al.  DNA-dependent Protein Kinase-mediated Phosphorylation of Protein Kinase B Requires a Specific Recognition Sequence in the C-terminal Hydrophobic Motif* , 2009, Journal of Biological Chemistry.

[30]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[31]  A. Joe,et al.  Oncogene addiction. , 2008, Cancer research.

[32]  J. Haveman,et al.  Clonogenic assay of cells in vitro , 2006, Nature Protocols.

[33]  D. Woodfield Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[34]  J. Higginson International Agency for Research on Cancer. , 1968, WHO chronicle.